Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 CAD | +4.76% | +15.79% | +4.76% |
08/04 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
28/03 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.49M 3.51B |
---|---|---|---|---|---|
Net income 2022 | -6M -8.21M -501M | Net income 2023 | -6M -8.21M -501M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.07M 65.46M | Net cash position 2023 | 808K 1.11M 67.47M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
1 day | +4.76% | ||
1 week | +15.79% | ||
Current month | +22.22% | ||
1 month | +22.22% | ||
3 months | +10.00% | ||
6 months | +10.00% | ||
Current year | +4.76% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 18/22/18 |
Director of Finance/CFO | 59 | 14/02 | |
Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 18/22/18 | |
Jacek Antas
CEO | Chief Executive Officer | - | 18/22/18 |
Malgorzata Laube
BRD | Director/Board Member | - | 08/22/08 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 0.22 | +4.76% | 3,505 |
26/24/26 | 0.21 | 0.00% | 15,300 |
25/24/25 | 0.21 | +7.69% | 18,100 |
24/24/24 | 0.195 | +2.63% | 2,000 |
23/24/23 | 0.19 | 0.00% | 20,272 |
Delayed Quote Toronto S.E., April 30, 2024 at 12:50 am IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.76% | 36.98M | |
+1.77% | 42.86B | |
+46.62% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- HBP Stock